Ambulatory TAVR: early feasibility experience during Covid-19 pandemic.

The COVID-19 pandemic has modified practice for patients with symptomatic aortic stenosis and could result in higher mortality due to treatment delays. In this clinical case series, three patients underwent ambulatory transcatheter aortic valve replacement (TAVR) thanks to patient and entourage willingness, careful patient selection (including a prior history of permanent pacemaker) and a minimalist procedural approach. No complications occurred during the 30-day follow-up. Performing ambulatory TAVR could reduce the clinical consequences of wait times, minimize exposure to coronavirus contamination and reduce the use of hospital resources that might be needed for COVID-19 patients.